Navigation Links
New Study Links dLife to Increased Rx Drug Usage Among Diabetes Consumers

WESTPORT, Conn., March 3 /PRNewswire-USNewswire/ -- A new study analyzing patient-level prescription data clearly demonstrates that dLife consumers take immediate and deeper action in treating their diabetes and co-morbid conditions after becoming engaged with dLife.  The study also confirms that dLife users test their blood sugar and take medications at a higher rate than non-dLife users.

In the study conducted by Crossix Solutions, Inc. ("Crossix"), the Rx purchasing habits of dLife members were analyzed prior to and after engaging with dLife.  In the period immediately following their engagement, as compared to the general population, more dLife diabetes consumers:

  • Begin Rx treatment for diabetes (+1600%)
  • Add insulin to their current treatment (+125%)
  • Switch from generic meds to branded (+50%)
  • Start test strip use (+700%)
  • Start on cholesterol (+160%) and high blood pressure meds (+150%)

Also, dLife diabetes consumers have higher adherence with their Rx purchase behavior demonstrating higher utilization of insulin (+9%) and test strip usage (+21%) in the post-engagement period.

"We have repeatedly found through our A&U studies over the years that dLife both attracts active health managers and also creates them.  And now we have the 3rd party Rx data to support it," says Howard Steinberg, CEO & Founder of dLife.  "There are so many who know they should be doing more but until they find dLife they don't know how to get there or can't find the motivation to start.  Across our media, everyone can find information they understand and enjoy, educational tools that truly help them learn, and inspiration from others to make lasting changes in their daily diabetes routine.  More aggressive therapeutic management of diabetes and co-morbid conditions is often as simple as lifestyle adjustments."

dLife, the only multimedia network serving the diabetes community, touches over 5 million active diabetes managers through the award-winning television show, dLifeTV, the only lifestyle TV series for people with diabetes, and, attracting 1 million diabetes visitors every month making it the leading online destination for diabetes information, inspiration, and connection.

About dLife

dLife is the only multimedia network serving the diabetes community. Its award-winning multimedia outlets include dLifeTV, the only lifestyle TV series for people with diabetes, airing every Sunday on CNBC at 7:00PM ET and 4:00PM PT., with over 80,000 pages of superior content, 9,000 diabetic recipes, and over 400 videos is the leading online destination for diabetes information, inspiration, and connection. The dLife network also includes dLifeRadio, featuring the dLife Diabetes Minute, heard on stations around the country and on XM Satellite Radio; dLifeDirect, the only diabetes cooperative direct-mail program; professional programs; and more.

About Crossix

Crossix Solutions, Inc. was founded in 2004 by a team that combines pharmaceutical and marketing experience with technology and analytical expertise. Their patent-pending, privacy-safe Crossix Scoreboard™ utilizes patient level Rx data from a proprietary network of pharmacies, PBMs and other healthcare organizations to analyze and optimize the impact of consumer marketing and patient adherence programs.


Back to top
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
(Date:6/23/2016)... -- The Biotechnology industry might still be ... opportunities to investors. assesses the recent performances of ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):